Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) Stock Analysis

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 2.35% and Operating profit at 10.53% over the last 5 years

Flat results in Jun 25

With ROE of 7.28%, it has a fair valuation with a 7.15 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 61,030 Million (Large Cap)

P/E

98.00

Industry P/E

Dividend Yield

0.91%

Debt Equity

-0.25

Return on Equity

7.28%

Price to Book

7.15

Revenue and Profits:

Net Sales:

1,054 Million

(Quarterly Results - Jun 2025)

Net Profit:

173 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

13.37%

6 Months

35.94%

1 Year

81.0%

2 Years

86.68%

3 Years

80.31%

4 Years

123.54%

5 Years

121.78%

Shenzhen Salubris Pharmaceuticals Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Shenzhen Salubris Pharmaceuticals Hits Day Low Amid Price Pressure at CNY 52.94

Shenzhen Salubris Pharmaceuticals faced a challenging trading day on October 14, 2025, with a notable stock decline. Despite recent setbacks, the company has shown strong annual performance, significantly outperforming the broader market. It maintains a solid market capitalization and return on equity, though profit trends have declined slightly.

Shenzhen Salubris Pharmaceuticals Hits Day Low Amid Price Pressure at CNY 54.68

Shenzhen Salubris Pharmaceuticals Co., Ltd. faced a decline in stock value on October 13, 2025, with a notable drop over the past week. Despite recent challenges, the company has demonstrated strong long-term growth, achieving a significant increase over the past year and year-to-date, alongside solid financial metrics.

Shenzhen Salubris Pharmaceuticals Hits Day High with Strong 3.42% Surge

Shenzhen Salubris Pharmaceuticals Co., Ltd. has shown strong performance, with a significant increase on September 25, 2025, and a robust weekly gain. Over the past year, the company has achieved impressive growth, maintaining a high dividend yield and strong valuation metrics despite a recent decline in profits.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.35%

EBIT Growth (5y)

10.53%

EBIT to Interest (avg)

32.71

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.19

Sales to Capital Employed (avg)

0.44

Tax Ratio

3.14%

Dividend Payout Ratio

92.59%

Pledged Shares

Institutional Holding

ROCE (avg)

7.91%

ROE (avg)

7.07%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

7.15

EV to EBIT

114.91

EV to EBITDA

62.65

EV to Capital Employed

9.21

EV to Sales

14.55

PEG Ratio

Dividend Yield

0.91%

ROCE (Latest)

8.02%

ROE (Latest)

7.28%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 12.14% vs 19.98% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 17.99% vs 15.03% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,054.30",
          "val2": "940.20",
          "chgp": "12.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "262.00",
          "val2": "229.90",
          "chgp": "13.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.00",
          "val2": "3.90",
          "chgp": "28.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.90",
          "val2": "3.90",
          "chgp": "-25.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "172.50",
          "val2": "146.20",
          "chgp": "17.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "145.60%",
          "val2": "138.80%",
          "chgp": "0.68%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 19.25% vs -3.30% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 4.20% vs -8.45% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,961.40",
          "val2": "3,321.80",
          "chgp": "19.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,080.40",
          "val2": "927.50",
          "chgp": "16.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "17.70",
          "val2": "17.90",
          "chgp": "-1.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-143.00",
          "val2": "-42.60",
          "chgp": "-235.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "605.20",
          "val2": "580.80",
          "chgp": "4.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "169.50%",
          "val2": "166.20%",
          "chgp": "0.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

1,054.30

940.20

12.14%

Operating Profit (PBDIT) excl Other Income

262.00

229.90

13.96%

Interest

5.00

3.90

28.21%

Exceptional Items

2.90

3.90

-25.64%

Consolidate Net Profit

172.50

146.20

17.99%

Operating Profit Margin (Excl OI)

145.60%

138.80%

0.68%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 12.14% vs 19.98% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 17.99% vs 15.03% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

3,961.40

3,321.80

19.25%

Operating Profit (PBDIT) excl Other Income

1,080.40

927.50

16.49%

Interest

17.70

17.90

-1.12%

Exceptional Items

-143.00

-42.60

-235.68%

Consolidate Net Profit

605.20

580.80

4.20%

Operating Profit Margin (Excl OI)

169.50%

166.20%

0.33%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 19.25% vs -3.30% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 4.20% vs -8.45% in Dec 2023

All Annual Results

Company CV

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Shenzhen Salubris Pharmaceuticals Co., Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 2.35% and Operating profit at 10.53% over the last 5 years

Flat results in Jun 25

With ROE of 7.28%, it has a fair valuation with a 7.15 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Shenzhen Salubris Pharmaceuticals Hits Day Low Amid Price Pressure at CNY 52.94

Shenzhen Salubris Pharmaceuticals Hits Day Low Amid Price Pressure at CNY 54.68

Shenzhen Salubris Pharmaceuticals Hits Day High with Strong 3.42% Surge

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

Company Coordinates